{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:07:09Z","timestamp":1792793229775,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["Y23H080005"],"award-info":[{"award-number":["Y23H080005"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00277-024-05730-y","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T01:02:11Z","timestamp":1712970131000},"page":"1833-1841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Therapeutic progress in relapsed\/refractory multiple myeloma"],"prefix":"10.1007","volume":"103","author":[{"given":"Qi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6120-8649","authenticated-orcid":false,"given":"Yamin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"issue":"5","key":"5730_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M et al (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327(5):464\u2013477","journal-title":"JAMA"},{"issue":"5","key":"5730_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/leu.2015.356","volume":"30","author":"J Laubach","year":"2016","unstructured":"Laubach J, Garderet L, Mahindra A et al (2016) Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 30(5):1005\u20131017","journal-title":"Leukemia"},{"issue":"10","key":"5730_CR3","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R et al (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18(10):1327\u20131337","journal-title":"Lancet Oncol"},{"issue":"8","key":"5730_CR4","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H et al (2018) Improvement in overall survival with Carfilzomib, Lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 36(8):728\u2013734","journal-title":"J Clin Oncol"},{"issue":"5","key":"5730_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1182\/blood.2019000722","volume":"134","author":"A Chari","year":"2019","unstructured":"Chari A, Martinez-Lopez J, Mateos MV et al (2019) Daratumumab plus Carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 134(5):421\u2013431","journal-title":"Blood"},{"issue":"1","key":"5730_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","volume":"13","author":"T Martin","year":"2023","unstructured":"Martin T, Dimopoulos MA, Mikhael J et al (2023) Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study. Blood Cancer J 13(1):72","journal-title":"Blood Cancer J"},{"issue":"17","key":"5730_CR7","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N et al (2016) Oral Ixazomib, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med 374(17):1621\u20131634","journal-title":"N Engl J Med"},{"issue":"12","key":"5730_CR8","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/ajh.26361","volume":"96","author":"PM Voorhees","year":"2021","unstructured":"Voorhees PM, Suman VJ, Tuchman SA et al (2021) A phase I\/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol 96(12):1595\u20131603","journal-title":"Am J Hematol"},{"key":"5730_CR9","doi-asserted-by":"crossref","unstructured":"Tang W, Li Y, Zhong X et al (2022) P953: PHASE I STUDY OF TQB3602 CAPSULE, AN ORAL PROTEASOME INHIBITOR, IN RELAPSED\/REFRACTORY MULTIPLE MYELOMA. HemaSphere. 6:843\u2013844","DOI":"10.1097\/01.HS9.0000846680.89917.3a"},{"issue":"9","key":"5730_CR10","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","volume":"4","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, Jung SH, Richardson PG et al (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4(9):e431\u2013e442","journal-title":"Lancet Haematol"},{"issue":"12","key":"5730_CR11","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Siegel DS, Vij R et al (2014) Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 123(12):1826\u20131832","journal-title":"Blood"},{"issue":"6","key":"5730_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M et al (2019) Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 20(6):781\u2013794","journal-title":"Lancet Oncol"},{"issue":"8","key":"5730_CR13","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari A, Suvannasankha A, Fay JW et al (2017) Daratumumab plus Pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood 130(8):974\u2013981","journal-title":"Blood"},{"issue":"3","key":"5730_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","volume":"23","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Perrot A, San-Miguel J et al (2022) Isatuximab plus Pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol 23(3):416\u2013427","journal-title":"Lancet Oncol"},{"issue":"2","key":"5730_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40265-015-0536-1","volume":"76","author":"K McKeage","year":"2016","unstructured":"McKeage K (2016) Daratumumab: First Global approval. Drugs 76(2):275\u2013281","journal-title":"Drugs"},{"issue":"6","key":"5730_CR16","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","volume":"7","author":"SZ Usmani","year":"2020","unstructured":"Usmani SZ, Nahi H, Plesner T et al (2020) Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol 7(6):e447\u2013e455","journal-title":"Lancet Haematol"},{"issue":"8","key":"5730_CR17","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00940","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Oriol A, Nahi H et al (2023) Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, Open-Label, phase III trial. J Clin Oncol 41(8):1590\u20131599","journal-title":"J Clin Oncol"},{"issue":"8","key":"5730_CR18","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K et al (2016) Daratumumab, Bortezomib, and Dexamethasone for multiple myeloma. N Engl J Med 375(8):754\u2013766","journal-title":"N Engl J Med"},{"issue":"1","key":"5730_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","volume":"23","author":"SZ Usmani","year":"2022","unstructured":"Usmani SZ, Quach H, Mateos MV et al (2022) Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol 23(1):65\u201376","journal-title":"Lancet Oncol"},{"issue":"14","key":"5730_CR20","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","volume":"7","author":"SZ Usmani","year":"2023","unstructured":"Usmani SZ, Quach H, Mateos MV et al (2023) Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Adv 7(14):3739\u20133748","journal-title":"Blood Adv"},{"issue":"5","key":"5730_CR21","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","volume":"7","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Nahi H, Legiec W et al (2020) Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol 7(5):e370\u2013e380","journal-title":"Lancet Haematol"},{"issue":"6","key":"5730_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M et al (2021) Daratumumab plus Pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 22(6):801\u2013812","journal-title":"Lancet Oncol"},{"issue":"5","key":"5730_CR23","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/bjh.16980","volume":"192","author":"A Chari","year":"2021","unstructured":"Chari A, Rodriguez-Otero P, McCarthy H et al (2021) Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label phase II study. Br J Haematol 192(5):869\u2013878","journal-title":"Br J Haematol"},{"issue":"9","key":"5730_CR24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40265-020-01311-1","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Isatuximab: first approval. Drugs 80(9):905\u2013912","journal-title":"Drugs"},{"issue":"10292","key":"5730_CR25","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J et al (2021) Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 397(10292):2361\u20132371","journal-title":"Lancet"},{"issue":"1","key":"5730_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","volume":"64","author":"B Balasa","year":"2015","unstructured":"Balasa B, Yun R, Belmar NA et al (2015) Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways. Cancer Immunol Immunother 64(1):61\u201373","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"5730_CR27","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-17-0998","volume":"17","author":"AT Kurdi","year":"2018","unstructured":"Kurdi AT, Glavey SV, Bezman NA et al (2018) Antibody-dependent Cellular phagocytosis by Macrophages is a Novel mechanism of action of Elotuzumab. Mol Cancer Ther 17(7):1454\u20131463","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"5730_CR28","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A et al (2015) Elotuzumab Therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):621\u2013631","journal-title":"N Engl J Med"},{"issue":"9","key":"5730_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Lonial S, White D et al (2020) Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 10(9):91","journal-title":"Blood Cancer J"},{"issue":"19","key":"5730_CR30","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S et al (2018) Elotuzumab plus Pomalidomide and Dexamethasone for multiple myeloma. N Engl J Med 379(19):1811\u20131822","journal-title":"N Engl J Med"},{"issue":"3","key":"5730_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1200\/JCO.21.02815","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S et al (2023) Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed\/Refractory multiple myeloma: final overall survival analysis from the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol 41(3):568\u2013578","journal-title":"J Clin Oncol"},{"issue":"12","key":"5730_CR32","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1038\/leu.2013.172","volume":"27","author":"J Schmidt","year":"2013","unstructured":"Schmidt J, Braggio E, Kortuem KM et al (2013) Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia 27(12):2357\u20132365","journal-title":"Leukemia"},{"issue":"1","key":"5730_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai YT, Landesman Y, Acharya C et al (2014) CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28(1):155\u2013165","journal-title":"Leukemia"},{"issue":"8","key":"5730_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M et al (2019) Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 381(8):727\u2013738","journal-title":"N Engl J Med"},{"issue":"10262","key":"5730_CR35","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I et al (2020) Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 396(10262):1563\u20131573","journal-title":"Lancet"},{"issue":"6","key":"5730_CR36","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Usmani SZ, Yong K (2021) CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol 8(6):e446\u2013e461","journal-title":"Lancet Haematol"},{"issue":"8","key":"5730_CR37","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N et al (2021) Idecabtagene Vicleucel in Relapsed and Refractory multiple myeloma. N Engl J Med 384(8):705\u2013716","journal-title":"N Engl J Med"},{"issue":"11","key":"5730_CR38","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B et al (2023) Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 388(11):1002\u20131014","journal-title":"N Engl J Med"},{"issue":"10297","key":"5730_CR39","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398(10297):314\u2013324","journal-title":"Lancet"},{"issue":"4","key":"5730_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K et al (2023) Cilta-cel or Standard Care in Lenalidomide-Refractory multiple myeloma. N Engl J Med 389(4):335\u2013347","journal-title":"N Engl J Med"},{"issue":"22","key":"5730_CR41","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD et al (2018) T cells genetically modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol 36(22):2267\u20132280","journal-title":"J Clin Oncol"},{"key":"5730_CR42","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent SA, Hoffmann FS, Kuhn PH et al (2015) \u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun 6:7333","journal-title":"Nat Commun"},{"issue":"1","key":"5730_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","volume":"12","author":"W Li","year":"2023","unstructured":"Li W, Zhang B, Cao W et al (2023) Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol 12(1):44","journal-title":"Exp Hematol Oncol"},{"issue":"9","key":"5730_CR44","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R et al (2023) Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 29(9):2295\u20132306","journal-title":"Nat Med"},{"issue":"14","key":"5730_CR45","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1182\/blood-2010-11-317438","volume":"118","author":"L Bodet","year":"2011","unstructured":"Bodet L, Gomez-Bougie P, Touzeau C et al (2011) ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 118(14):3901\u20133910","journal-title":"Blood"},{"issue":"5","key":"5730_CR46","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","volume":"15","author":"EA Punnoose","year":"2016","unstructured":"Punnoose EA, Leverson JD, Peale F et al (2016) Expression Profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist Venetoclax in multiple myeloma models. Mol Cancer Ther 15(5):1132\u20131144","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"5730_CR47","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/leu.2015.350","volume":"30","author":"SM Matulis","year":"2016","unstructured":"Matulis SM, Gupta VA, Nooka AK et al (2016) Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia 30(5):1086\u20131093","journal-title":"Leukemia"},{"issue":"22","key":"5730_CR48","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","volume":"130","author":"P Moreau","year":"2017","unstructured":"Moreau P, Chanan-Khan A, Roberts AW et al (2017) Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM. Blood 130(22):2392\u20132400","journal-title":"Blood"},{"issue":"12","key":"5730_CR49","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M et al (2020) Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21(12):1630\u20131642","journal-title":"Lancet Oncol"},{"issue":"4","key":"5730_CR50","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajh.26083","volume":"96","author":"JL Kaufman","year":"2021","unstructured":"Kaufman JL, Gasparetto C, Schjesvold FH et al (2021) Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma. Am J Hematol 96(4):418\u2013427","journal-title":"Am J Hematol"},{"key":"5730_CR51","unstructured":"Abbvie (2023) AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma. https:\/\/news.abbvie.com\/2023-09-29-AbbVie-Presents-Results-from-Phase-3-CANOVA-Study-of-Venetoclax-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma. Accessed 29 September 2023"},{"issue":"15","key":"5730_CR52","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A (2020) Belantamab Mafodotin: first approval. Drugs 80(15):1607\u20131613","journal-title":"Drugs"},{"issue":"2","key":"5730_CR53","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A et al (2020) Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 21(2):207\u2013221","journal-title":"Lancet Oncol"},{"issue":"23","key":"5730_CR54","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","volume":"129","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Cohen AD, Lee HC et al (2023) Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer 129(23):3746\u20133760","journal-title":"Cancer"},{"issue":"10","key":"5730_CR55","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A et al (2023) Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol 10(10):e801\u2013e812","journal-title":"Lancet Haematol"},{"issue":"12","key":"5730_CR56","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","volume":"15","author":"H Ikeda","year":"2009","unstructured":"Ikeda H, Hideshima T, Fulciniti M et al (2009) The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 15(12):4028\u20134037","journal-title":"Clin Cancer Res"},{"issue":"11","key":"5730_CR57","doi-asserted-by":"publisher","first-page":"e794","DOI":"10.1016\/S2352-3026(21)00208-8","volume":"8","author":"KR Kelly","year":"2021","unstructured":"Kelly KR, Ailawadhi S, Siegel DS et al (2021) Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1\/2a study. Lancet Haematol 8(11):e794\u2013e807","journal-title":"Lancet Haematol"},{"issue":"10301","key":"5730_CR58","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N et al (2021) Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398(10301):665\u2013674","journal-title":"Lancet"},{"issue":"6","key":"5730_CR59","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387(6):495\u2013505","journal-title":"N Engl J Med"},{"issue":"16","key":"5730_CR60","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","volume":"82","author":"C Kang","year":"2022","unstructured":"Kang C (2022) Teclistamab: first approval. Drugs 82(16):1613\u20131619","journal-title":"Drugs"},{"issue":"18","key":"5730_CR61","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1056\/NEJMc2211969","volume":"387","author":"E Hindi\u00e9","year":"2022","unstructured":"Hindi\u00e9 E (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387(18):1721","journal-title":"N Engl J Med"},{"key":"5730_CR62","doi-asserted-by":"crossref","unstructured":"Girgis S, Wang Lin SX, Pillarisetti K et al (2022) Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma. Blood Adv","DOI":"10.1182\/bloodadvances.2022007625"},{"issue":"8","key":"5730_CR63","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M et al (2021) Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv 5(8):2196\u20132215","journal-title":"Blood Adv"},{"issue":"15","key":"5730_CR64","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Edavettal S, Mendon\u00e7a M et al (2020) A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 135(15):1232\u20131243","journal-title":"Blood"},{"issue":"24","key":"5730_CR65","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG et al (2022) Talquetamab, a T-Cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387(24):2232\u20132244","journal-title":"N Engl J Med"},{"key":"5730_CR66","doi-asserted-by":"crossref","unstructured":"MonumenTAL Results for Talquetamab in Myeloma Cancer Discov 13(2):250\u2013251","DOI":"10.1158\/2159-8290.CD-NB2022-0079"},{"key":"5730_CR67","doi-asserted-by":"crossref","unstructured":"Lee H, Neri P, Bahlis NJ (2024) BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: Efficacy, safety and resistance mechanisms. Blood","DOI":"10.1182\/blood.2023022499"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05730-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05730-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05730-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T07:08:34Z","timestamp":1715584114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05730-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["5730"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05730-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,13]]},"assertion":[{"value":"16 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}